Last deal
Amount
Stage
Date
all rounds
Total amount
date founded
Financing round
General
About Company
Related to
Metabolomic Diagnostics
Metabolomic Diagnostics develops novel biomarker-based diagnostic solutions for complex diseases.
Sector
Subsector
Location
total rounds
total raised
Industry
Sector :
Subsector :
Keywords :
founded date
founders
Number of employees
Company Type
Last funding type
IPO status
Contacts
location
Contact Email
Phone number
Website URL
Similar Companies1000
COYOTE
Coyote Bioscience develops genetic molecular diagnostic technology for healthcare solutions.
Sector
Subsector
Keywords
Location
total rounds
total raised
Multiplicom
Multiplicom is a biotech company that develops molecular diagnostic kits.
Sector
Subsector
Keywords
Location
total rounds
total raised
Cernostics
Cernostics is a life science company that develops molecular diagnostic tests to fight cancer.
Sector
Subsector
Keywords
Location
total rounds
total raised
Biotheranostics
Biotheranostics provides molecular diagnostic tests to support cancer treatment in San Diego.
Sector
Subsector
Location
total rounds
total raised
Financials
Funding Rounds1
Number of Funding Rounds
Money Raised
Their latest funding was raised on 01.05.2015. Their latest investor EASME - EU Executive Agency for SMEs. Their latest round Grant
EASME - EU Executive Agency for SMEs
EASME manages EU programs for SMEs, environment, energy, and maritime projects.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Co-Investors
Investors1
Number of lead investors
Number of investors
EASME - EU Executive Agency for SMEs
EASME manages EU programs for SMEs, environment, energy, and maritime projects.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
People
Founders3
Charles Garvey
Charles Garvey is a serial entrepreneur with extensive experience in growing Irish companies internationally. From 1990 to 2003 he was first COO and then CEO of Horizon Technology Group Plc. and took Horizon from a small privately held company to a major European multinational with significant global credentials. Charles took Horizon public on the London and Dublin stock exchange in 2000. Charles continued to work with Horizon right up to its sale to Avnet Corp in 2009. From 2006 to 2011 Charles was CEO of NitroSell Ltd., a SAAS based ecommerce platform, which has generated almost $1B in sales to date. Charles continues to serve as non-executive chairman of NitroSell. For the past six years, Charles has used his proven teambuilding and managerial skills to build a focused, motivated and successful team of life science professionals at Metabolomic Diagnostics. Charles has extensive experience at forging and managing partnerships with major multinational companies and in corporate finance and fundraising through angel investors, VCs, banks and public markets.
current job
organization founded
Charles Garvey
Robin Tuytten
Dr Tuytten is a globally respected leader in the field of mass spectrometry and women’s health. Prior to his appointment as CEO Robin had been leading the Metabolomic Diagnostics R&D programs. Robin is trained as an analytical chemist and holds a PhD from the University of Antwerp where he developed methodologies for the mass spectrometric analyses of nucleosides and nucleotides. He joined Belgian biomarker company Pronota in 2006. Robin led Pronota’s Preeclampsia biomarker program until he joined Metabolomic Diagnostics. With more than 20 peer reviewed scientific publications, co-inventorship on several technical and biomarker patent applications including protein biomarkers for PE, a solid track record in commercial biomarker development and a deep knowledge of the field of pregnancy diseases, Robin Tuytten is well positioned to lead the company’s current and future product development efforts.
current job
organization founded
Robin Tuytten
Diarmuid Cahalane
Diarmuid Cahalane has been consulting to the technology and life sciences sectors for over 20 years. He is recognised for his strengths in risk analysis, remediation, cost reduction and compliance. In 1997, he established his own regulatory consulting company, and went on to work with many of the leading life science companies, including Pfizer, Schering Plough, and Glaxo Smithkline. His level of expertise in Medical Devices is particularly strong given that he has worked on validation of software as a medical device with Guidant, Johnson & Johnson, and Nellcor Puritan Bennett. He contributed to the Pharmaceutical Industry Computer Systems Validation Forum (PICSVF) in 1994, which subsequently became known as the Good Automated Manufacturing Practice (GAMP) forum. In 1997 he participated in meetings with the FDA prior to the publication of 21 CFR Part 11. In 1999, he signed a global professional services agreement with Schering Plough, which led to his company completing projects in Singapore, US, and Germany as part of a global Computer Systems Validation Remediation Project. Diarmuid has also successfully provided accreditation services to hospitals enabling them to get their pathology laboratories accredited to ISO15189 Quality Standards. Hospital clients included the Mater Private, St. James’s, Beaumont, The Bon Secours Health System, St. Lukes, The National Orthopaedic Hospital, The National Children’s Hospital and many others. He has presented guest lectures to students in the Department of Process Engineering at University College Cork, and also at St.James’s Hospital in Dublin. His company, Open Innovation Partners, is part of a European Consortium, “BioApp- Biodesign For Health” which aims to integrate innovation into the undergraduate curriculum across Europe through formulated design methodologies leading to accelerated application of Biomedical Technologies in the Clinical Setting. Funded by the European Union, the project is led by University College Cork, in conjunction with Universities in the Netherlands, Belgium, and Hungary. Diarmuid is a regular speaker at major Business conferences including the European Compliance Academy in Germany and validation conferences in Puerto Rico and the US. He maintains contact with the FDA at a high level and recently visited Washington DC to discuss innovative new theranostics concepts with the FDA, Patient Advocacy Groups and others. He spoke at the International Critical Markers Of Disease (CMOD) Conference in Dublin Castle in May 2012, the EU-US Standardisation Conference in the RCSI in February of this year, and most recently at the SMEST Conference in Brussels, Belgium.
current job
organization founded
Diarmuid Cahalane
Employee Profiles4
Robin Tuytten
Co-Founder & Vice President, Research & Development